These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32959073)

  • 21. Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.
    Tsai CY; Hsieh SC; Wu TH; Li KJ; Shen CY; Liao HT; Wu CH; Kuo YM; Lu CS; Yu CL
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy.
    Henry TW; Mendoza FA; Jimenez SA
    Autoimmun Rev; 2019 Nov; 18(11):102396. PubMed ID: 31520794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope.
    Hinchcliff M; O'Reilly S
    Curr Rheumatol Rep; 2020 Jun; 22(8):42. PubMed ID: 32562016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis.
    Henderson J; Brown M; Horsburgh S; Duffy L; Wilkinson S; Worrell J; Stratton R; O'Reilly S
    Rheumatology (Oxford); 2019 Mar; 58(3):527-535. PubMed ID: 30462328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
    Asano Y; Varga J
    Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
    Bhattacharyya S; Wei J; Varga J
    Nat Rev Rheumatol; 2011 Oct; 8(1):42-54. PubMed ID: 22025123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
    Asano Y
    Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods.
    Xu X; Ramanujam M; Visvanathan S; Assassi S; Liu Z; Li L
    PLoS One; 2020; 15(11):e0242863. PubMed ID: 33253326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global hypomethylation pattern in systemic sclerosis: An application for absolute quantification of epigenetic DNA modification products by 2D-UPLC-MS/MS.
    Dal-Bekar NE; Siomek-Gorecka A; Gackowski D; Köken-Avşar A; Yarkan-Tuğsal H; Birlik M; İşlekel H
    Clin Immunol; 2022 Jun; 239():108997. PubMed ID: 35398518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deregulation of long noncoding RNAs ANCR, TINCR, HOTTIP and SPRY4-IT1 in plasma of systemic sclerosis patients: SPRY4-IT1 as a novel biomarker of scleroderma and its subtypes.
    Abd-Elmawla MA; Hassan M; Elsabagh YA; Alnaggar ARLR; Senousy MA
    Cytokine; 2020 Sep; 133():155124. PubMed ID: 32442909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical roles of microRNAs in the pathogenesis of systemic sclerosis: New advances, challenges and potential directions.
    Miao CG; Xiong YY; Yu H; Zhang XL; Qin MS; Song TW; Du CL
    Int Immunopharmacol; 2015 Sep; 28(1):626-33. PubMed ID: 26241784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanisms.
    Doskaliuk B; Zaiats L; Yatsyshyn R; Gerych P; Cherniuk N; Zimba O
    Rheumatol Int; 2020 Oct; 40(10):1555-1569. PubMed ID: 32715342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy.
    Castelino FV; Varga J
    Curr Opin Rheumatol; 2014 Nov; 26(6):607-14. PubMed ID: 25191991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unfolding the pathogenesis of scleroderma through genomics and epigenomics.
    Tsou PS; Sawalha AH
    J Autoimmun; 2017 Sep; 83():73-94. PubMed ID: 28526340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.